(DIR) Home
Promino Nutritional Sciences and Dr. Patrick Gunning to Begin
Preclinical Studies Focused on Targeted Nutritional Supplementation
for Cancer Patients
(HTM) Source
----------------------------------------------------------------------
_The preclinical study will test the Company's p_ _atented amino acid
formula_ _'s efficacy in mitigating muscle loss in cancer patients_
BURLINGTON, ON, May 8, 2024 /CNW/ - Promino Nutritional Sciences Inc.
(CSE: MUSL) (OTC: MUSLF) (FRANKFURT: 93X) (the "Company" or "Promino")
is pleased to announce it has retained award winning PhD Dr. Patrick
Gunning to assess preclinical studies conducted on its patented
formulation's mitigation of muscle loss in cancer patients. Dr.
Gunning will be joining the Company as a special advisor on various
preclinical studies over the next 12 months.
Dr. Patrick Gunning (CNW Group/Promino Nutritional Sciences Inc.)
Dr. Patrick Gunning is a Professor of Chemistry at the University of
Toronto, Canada, Research Chair in Medicinal Chemistry, and Founder
and Chief Scientific Director of the Centre for Medicinal Chemistry
(UofT). Patrick obtained his PhD at the University of Glasgow in 2005.
Over the last 17 years he has developed a dynamic and diverse
medicinal chemistry program targeting disease-relevant proteins. Dr.
Gunning has published over 130 papers, won over 20 research awards,
including being named in Canada's Top 40 under 40.
The prevalence of muscle loss among cancer patients has been reported
as between 20% and 70% depending on the type of tumor and the criteria
used for assessment. Nutritional interventions should be an essential
part of the multimodal approach to cancer. There are an estimated
_17,113,494_ _people suffering from cancer in the United States
alone._
"I am excited about this opportunity to evaluate Promino's core patent
for mitigating weight loss in preclinical trials of many different
human cancers," explained Professor Gunning. "Improving the lives of
cancer patients has been a life-long endeavor, and to play a role in
evaluating a product that could actually help make a positive impact
is important to me. High energy consuming tumors coupled with
aggressive chemotherapy treatments often lead to severe weight loss in
cancer patients, causing the patient fatigue, poor quality of life -
and ultimately - poor clinical outcomes."
"The health care industry has been moving toward personalized medicine
since the mapping of the genome," stated Vito Sanzone, CEO of Promino
Nutritional Sciences. "Designing personalized nutraceutical
supplements for specific diseases is the natural next step. We are
very excited about these studies to explore specific amino acid based
supplements from our core patented technologies to enhance the lives
of cancer patients globally. We couldn't be more pleased to have the
calibre of Professor Gunning involved in this project."
**About Promino™ and Rejuvenate Muscle™ Brands**
Promino™ and Rejuvenate Muscle™ functional beverages utilize a
patented formula from the University of Arkansas, led by Dr. Robert
Wolfe, and is the result of over USD $20 million in research, over 25
human clinical trials on muscle repair, recovery and muscle protein
synthesis over 23 years. The Promino™ Patented Plant-Based Blend
contains nine essential amino acids in the precise combination to
trigger fast muscle growth and recovery. The fast-absorbing beverages
provide the body with the building blocks of protein faster, without
the excess calories, filler and carbohydrates of conventional whey or
plant proteins.
The Promino™ Patented Plant-Based Blend is the highest-ranking source
of protein quality on the DIAAS score (321) versus whey protein (109).
DIAAS is the new gold standard testing for digestible protein quality
adopted by the World Health Organization.
**About Promino Nutritional Sciences, Inc.**
Promino is an innovative and research driven Canadian nutraceutical
company founded in 2015 and located in Burlington, Ontario,
specializing in the development of patented and science-based products
for the global consumer packaged goods market utilizing the Promino
Patented Plant-Based Blend.
Flagship brand Promino™ (11 grams of Promino blend) is a drink mix for
athletes, weekend warriors and active individuals shown to be two
times more effective than whey protein at building muscle. Promino
Brand Ambassadors include NHL player Jack Eichel of the Vegas Golden
Knights, MLB and Toronto Blue Jays legend and owner of the USL
Champion League Las Vegas Lights Jose Bautista and NHL legend Kirk
McLean of the Vancouver Canucks. Promino™ is NSF Certified for Sport™
which means it is free of banned substances and approved for use by
all professional sports leagues.
Rejuvenate Muscle™ (3.6 grams of Promino Blend) is a daily muscle
health beverage clinically proven to assist in the building,
rebuilding, restoration and rejuvenation of natural muscle mass and
helps prevent age-related muscle loss.
To learn more about Promino and it products visit
http://www.drinkpromino.com
**Forward-Looking Statements**
This news release contains "forward-looking information" and "forward-
looking statements" (collectively, "forward-looking statements")
within the meaning of applicable Canadian securities legislation. All
statements, other than statements of historical fact, are forward-
looking statements and are based on expectations, estimates and
projections as at the date of this news release. All statements that
address activities, events, or developments that the Company expects
or anticipates will, or may, occur in the future, are forward-looking
statements, including statements regarding: the potential outcomes of
pre-clinical studies, including any clinical applications and benefits
of Promino's products; product launch dates; the expected effect of
the Promino™ and Rejuvenate™ products on the protein market, the
Company and its business, including any anticipated benefits to the
Company; and the Company's business prospects, future trends, plans
and strategies. In some cases, forward looking statements are preceded
by, followed by, or include words such as "may", "will," "would",
"could", "should", "believes", "estimates", "projects", "potential",
"expects", "plans", "anticipates", "continues", or the negative of
those words or other similar or comparable words. In preparing the
forward-looking statements in this news release, the Company has
applied several material assumptions, including, but not limited to,
that general business and economic conditions will not change in a
materially adverse manner. These forward-looking statements are based
on reasonable assumptions and estimates of management of the Company
at the time such statements were made. Actual future results may
differ materially as forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of the Company to
materially differ from any future results, performance or achievements
expressed or implied by such forward-looking statements. Although the
forward-looking statements contained in this news release are based
upon what management of the Company believes, or believed at the time,
to be reasonable assumptions, the Company cannot assure shareholders
that actual results will be consistent with such forward-looking
statements, as there may be other factors that cause results not to be
as anticipated, estimated or intended. Readers should not place undue
reliance on the forward-looking statements and information contained
in this news release. The Company assumes no obligation to update the
forward-looking statements of beliefs, opinions, projections, or other
factors.
** _No stock exchange, securities commission or other regulatory
authority has approved or disapproved the information contained
herein._**
SOURCE Promino Nutritional Sciences Inc.
For further information: Vito Sanzone, [email protected], 289-348-1970
ext. 222; Marc Charbin, Investor Relations, [email protected],
416-467-5229.
______________________________________________________________________
Served by Flask-Gopher/2.2.1